MedTrace Logo

C11 ER176 PET in Evaluating Neuroinflammation in Patients With Post-COVID Syndrome

NCT07527130 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2026-04-24

No results posted yet for this study

Summary

The purpose of this research is to find out if Positron Emission Tomography (PET) imaging with an investigational drug called C-11 ER176 can help us learn more about Post-COVID Syndrome.

Conditions

Interventions

DRUG

C11 ER176 Tracer

C11 ER176 tracer will be administered by IV, followed by PET imaging of the brain to evaluate for neuroinflammation

Sponsors & Collaborators

Principal Investigators

  • Ryan T. Hurt, MD, PhD · Mayo Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2027-12-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07527130 on ClinicalTrials.gov